JP2004501161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501161A5 JP2004501161A5 JP2002504283A JP2002504283A JP2004501161A5 JP 2004501161 A5 JP2004501161 A5 JP 2004501161A5 JP 2002504283 A JP2002504283 A JP 2002504283A JP 2002504283 A JP2002504283 A JP 2002504283A JP 2004501161 A5 JP2004501161 A5 JP 2004501161A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- glycopeptide
- hydrogen
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical group NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 36
- 102000002068 Glycopeptides Human genes 0.000 description 36
- 108010015899 Glycopeptides Proteins 0.000 description 36
- 229910052739 hydrogen Inorganic materials 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 23
- 125000000392 cycloalkenyl group Chemical group 0.000 description 18
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 150000001720 carbohydrates Chemical group 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- 125000005017 substituted alkenyl group Chemical group 0.000 description 12
- 125000000547 substituted alkyl group Chemical group 0.000 description 12
- 125000004426 substituted alkynyl group Chemical group 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 9
- -1 N- (phosphonomethyl) aminomethyl Chemical group 0.000 description 7
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21341000P | 2000-06-22 | 2000-06-22 | |
| PCT/US2001/013998 WO2001098328A2 (en) | 2000-06-22 | 2001-05-01 | Glycopeptide phosphonate derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006304562A Division JP2007045842A (ja) | 2000-06-22 | 2006-11-09 | グリコペプチドホスホネート誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501161A JP2004501161A (ja) | 2004-01-15 |
| JP2004501161A5 true JP2004501161A5 (enExample) | 2006-05-25 |
| JP3900491B2 JP3900491B2 (ja) | 2007-04-04 |
Family
ID=22795013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504283A Expired - Fee Related JP3900491B2 (ja) | 2000-06-22 | 2001-05-01 | グリコペプチドホスホネート誘導体 |
| JP2006304562A Pending JP2007045842A (ja) | 2000-06-22 | 2006-11-09 | グリコペプチドホスホネート誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006304562A Pending JP2007045842A (ja) | 2000-06-22 | 2006-11-09 | グリコペプチドホスホネート誘導体 |
Country Status (36)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE242783T1 (de) * | 1998-12-23 | 2003-06-15 | Theravance Inc | Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten |
| US6770621B2 (en) | 2000-05-02 | 2004-08-03 | Theravance, Inc. | Polyacid glycopeptide derivatives |
| EP1278549B1 (en) | 2000-05-02 | 2008-12-10 | Theravance, Inc. | Composition containing a cyclodextrin and a glycopeptide antibiotic |
| US6828299B2 (en) | 2000-06-22 | 2004-12-07 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| ATE388960T1 (de) | 2000-06-22 | 2008-03-15 | Theravance Inc | Glykopeptidderivate mit carboxysacchariden |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| US6872804B2 (en) | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| TWI312785B (en) | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| TWI275594B (en) | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI233932B (en) * | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
| WO2003099858A1 (en) | 2002-05-24 | 2003-12-04 | Theravance, Inc. | Cross-linked glycopeptide-cephalosporin antibiotics |
| WO2003106399A2 (en) | 2002-06-17 | 2003-12-24 | Theravance, Inc. | PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS |
| WO2004110473A1 (en) * | 2003-05-27 | 2004-12-23 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| EP1654036B1 (en) * | 2003-07-22 | 2007-12-26 | Theravance, Inc. | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| AU2007204755A1 (en) * | 2006-01-10 | 2007-07-19 | Eugene J. Van Scott | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
| JP2008112847A (ja) * | 2006-10-30 | 2008-05-15 | Shin Etsu Chem Co Ltd | 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池 |
| AU2007336674A1 (en) | 2006-12-22 | 2008-07-03 | Targanta Therapeutics, Inc. | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| US20090069219A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched telavancin |
| EP2217224B1 (en) | 2007-11-09 | 2019-05-08 | Basf As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| KR20100109936A (ko) * | 2007-12-26 | 2010-10-11 | 리드 테라퓨틱스, 인크. | 항박테리아제로서의 신규한 반(半)-합성 글리코펩티드 |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| WO2010048340A2 (en) * | 2008-10-24 | 2010-04-29 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
| GB2465863A (en) * | 2008-12-05 | 2010-06-09 | Lead Therapeutics Inc | Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections |
| US9682061B2 (en) | 2009-04-28 | 2017-06-20 | The Medicines Company | Methods of treating bacterial infections using oritavancin |
| HRP20190732T1 (hr) | 2009-05-08 | 2019-06-14 | Basf As | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti |
| WO2011005959A1 (en) * | 2009-07-09 | 2011-01-13 | Plus Chemicals Sa | Process for the preparation of n-protected-decylaminoethanal |
| SG10201509127YA (en) | 2010-11-05 | 2015-12-30 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| EP2753638A1 (en) | 2011-09-09 | 2014-07-16 | Sandoz AG | Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof |
| EP2753637A1 (en) | 2011-09-09 | 2014-07-16 | Sandoz AG | Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin |
| JP5724937B2 (ja) * | 2012-04-23 | 2015-05-27 | ニプロ株式会社 | 腎臓集積性を示すペプチド、製剤 |
| CN103897040B (zh) * | 2012-12-27 | 2018-05-22 | 浙江医药股份有限公司新昌制药厂 | 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途 |
| KR102213143B1 (ko) | 2013-02-28 | 2021-02-08 | 바스프 에이에스 | 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법 |
| EP2969004B1 (en) | 2013-03-15 | 2026-02-25 | Melinta Subsidiary Corp. | Delafloxacin for use in treating infections in obese patients |
| CN105085636B (zh) * | 2014-05-19 | 2020-05-01 | 中国医学科学院药物研究所 | 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用 |
| CN107257689A (zh) | 2015-02-23 | 2017-10-17 | 施万生物制药抗生素Ip有限责任公司 | 投予特拉万星(telavancin)的剂量和方法 |
| CN107530306A (zh) | 2015-04-28 | 2018-01-02 | 普罗诺瓦生物医药挪威公司 | 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途 |
| CN106188243B (zh) * | 2015-05-05 | 2020-06-26 | 博瑞生物医药（苏州）股份有限公司 | 一种奥利万星的制备方法 |
| US20200171124A1 (en) | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| SG11201809908TA (en) * | 2016-05-09 | 2018-12-28 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| IL270685B (en) | 2017-05-22 | 2022-09-01 | Insmed Inc | Cleavable derivatives of lipoglycopeptide and their uses |
| CN107629116B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107629115B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107987131B (zh) * | 2017-11-16 | 2021-03-09 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的化合物、其制备方法和应用 |
| ES2996688T3 (en) | 2017-12-06 | 2025-02-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| CN108409837B (zh) | 2018-03-06 | 2021-09-24 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用 |
| JP2022507357A (ja) * | 2018-11-21 | 2022-01-18 | インスメッド インコーポレイテッド | リポグリコペプチドクリーバブル誘導体およびそれらの使用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872A (en) * | 1849-11-13 | Means of changing the combination in bevolving tumbler-locks | ||
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| US4639433A (en) * | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| CA2031803C (en) * | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
| US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| WO1994012217A1 (en) | 1992-12-02 | 1994-06-09 | Insite Vision Incorporated | Cyclodextrin and polymer based drug delivery system |
| US6077822A (en) * | 1993-09-14 | 2000-06-20 | Dumex-Alpharma A/S | Drug salts |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| AU703106B2 (en) * | 1994-01-28 | 1999-03-18 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| US5614615A (en) * | 1995-03-21 | 1997-03-25 | The Scripps Research Institute | Sialyl Lewis X mimetics incorporating fucopeptides |
| US5919756A (en) | 1996-06-28 | 1999-07-06 | Eli Lilly And Company | Amides |
| US6391851B1 (en) * | 1997-03-10 | 2002-05-21 | Fujisawa Pharmaceutical Co., Ltd. | Hydrochlorides of vancomycin antibiotics and process for producing the same |
| US5916873A (en) | 1997-04-17 | 1999-06-29 | Eli Lilly And Company | Teicoplanin derivatives |
| US6323176B1 (en) * | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| EP1095058A4 (en) | 1998-07-14 | 2003-07-16 | Univ Princeton | GLYCOPEPTIDANTIBIOTICS, COMBINATIONAL LIBRARIES OF GLYCOPEPTIDANTIBIOTICS AND METHOD FOR THEIR PRODUCTION |
| ATE242783T1 (de) * | 1998-12-23 | 2003-06-15 | Theravance Inc | Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten |
| DE19911097A1 (de) | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
| US6518243B1 (en) | 1999-04-02 | 2003-02-11 | Trustees Of Princeton University | Desleucyl glycopeptide antibiotics and methods of making same |
| JP2000302687A (ja) | 1999-04-22 | 2000-10-31 | Sagami Chem Res Center | 抗菌性オリゴマー及び抗菌剤 |
| US6770621B2 (en) | 2000-05-02 | 2004-08-03 | Theravance, Inc. | Polyacid glycopeptide derivatives |
| EP1278549B1 (en) | 2000-05-02 | 2008-12-10 | Theravance, Inc. | Composition containing a cyclodextrin and a glycopeptide antibiotic |
| BR0112393A (pt) | 2000-06-21 | 2003-07-08 | Internat Health Man Associates | Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais |
| US6828299B2 (en) | 2000-06-22 | 2004-12-07 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| AU2001259302A1 (en) | 2000-06-22 | 2002-01-02 | Yongqi Mu | Glycopeptide disulfide and thioester derivatives |
| ATE388960T1 (de) | 2000-06-22 | 2008-03-15 | Theravance Inc | Glykopeptidderivate mit carboxysacchariden |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI275594B (en) * | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI233932B (en) * | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
-
2001
- 2001-01-05 UA UA2003010499A patent/UA75083C2/uk unknown
- 2001-04-27 MY MYPI20012000 patent/MY127081A/en unknown
- 2001-04-29 EG EG2001040429A patent/EG26726A/en active
- 2001-04-30 AR ARP010102060A patent/AR035333A1/es active IP Right Grant
- 2001-05-01 AU AU2001261107A patent/AU2001261107B2/en not_active Expired
- 2001-05-01 HR HR20020888A patent/HRP20020888B1/xx not_active IP Right Cessation
- 2001-05-01 KR KR1020027017472A patent/KR100768488B1/ko not_active Expired - Lifetime
- 2001-05-01 MX MXPA02012745A patent/MXPA02012745A/es active IP Right Grant
- 2001-05-01 RS YUP-969/02A patent/RS50499B/sr unknown
- 2001-05-01 IL IL152408A patent/IL152408A/en unknown
- 2001-05-01 NZ NZ522279A patent/NZ522279A/en not_active IP Right Cessation
- 2001-05-01 HU HU0301320A patent/HU229370B1/hu not_active IP Right Cessation
- 2001-05-01 US US09/847,042 patent/US6635618B2/en not_active Expired - Lifetime
- 2001-05-01 CN CNB018113508A patent/CN100469788C/zh not_active Expired - Lifetime
- 2001-05-01 HK HK03104490.4A patent/HK1052191B/en not_active IP Right Cessation
- 2001-05-01 JP JP2002504283A patent/JP3900491B2/ja not_active Expired - Fee Related
- 2001-05-01 DK DK01934967T patent/DK1292612T3/da active
- 2001-05-01 CZ CZ20023942A patent/CZ303672B6/cs not_active IP Right Cessation
- 2001-05-01 EA EA200300050A patent/EA005953B1/ru not_active IP Right Cessation
- 2001-05-01 AT AT01934967T patent/ATE337334T1/de active
- 2001-05-01 CA CA2411590A patent/CA2411590C/en not_active Expired - Lifetime
- 2001-05-01 BR BRPI0111222A patent/BRPI0111222B8/pt not_active IP Right Cessation
- 2001-05-01 SK SK1852-2002A patent/SK287470B6/sk not_active IP Right Cessation
- 2001-05-01 EP EP01934967A patent/EP1292612B1/en not_active Expired - Lifetime
- 2001-05-01 CA CA2713965A patent/CA2713965A1/en not_active Abandoned
- 2001-05-01 SI SI200130642T patent/SI1292612T1/sl unknown
- 2001-05-01 TW TW090110397A patent/TWI305209B/zh not_active IP Right Cessation
- 2001-05-01 AU AU6110701A patent/AU6110701A/xx active Pending
- 2001-05-01 DE DE60122516T patent/DE60122516T2/de not_active Expired - Lifetime
- 2001-05-01 WO PCT/US2001/013998 patent/WO2001098328A2/en not_active Ceased
- 2001-05-01 ES ES01934967T patent/ES2271012T3/es not_active Expired - Lifetime
- 2001-05-01 PL PL359419A patent/PL207101B1/pl unknown
- 2001-05-01 PT PT01934967T patent/PT1292612E/pt unknown
-
2002
- 2002-10-29 IS IS6600A patent/IS2303B/is unknown
- 2002-11-19 ZA ZA200209419A patent/ZA200209419B/en unknown
- 2002-12-11 NO NO20025954A patent/NO330360B1/no not_active IP Right Cessation
-
2003
- 2003-05-12 US US10/436,341 patent/US6872701B2/en not_active Expired - Lifetime
- 2003-09-24 US US10/669,778 patent/US6887976B2/en not_active Expired - Lifetime
-
2005
- 2005-01-18 US US11/037,934 patent/US7008923B2/en not_active Expired - Lifetime
- 2005-11-02 US US11/265,570 patent/US7208471B2/en not_active Expired - Lifetime
-
2006
- 2006-09-04 CY CY20061101256T patent/CY1105194T1/el unknown
- 2006-10-23 US US11/584,908 patent/US7351691B2/en not_active Expired - Lifetime
- 2006-11-09 JP JP2006304562A patent/JP2007045842A/ja active Pending
-
2007
- 2007-10-24 US US11/977,429 patent/US7700550B2/en not_active Expired - Fee Related
-
2010
- 2010-03-02 US US12/715,554 patent/US8101575B2/en not_active Expired - Fee Related
-
2011
- 2011-11-18 NO NO2011025C patent/NO2011025I1/no not_active IP Right Cessation
- 2011-11-30 DE DE201112100062 patent/DE122011100062I1/de active Pending
- 2011-11-30 LU LU91908C patent/LU91908I2/fr unknown
- 2011-12-16 US US13/328,284 patent/US8541375B2/en not_active Expired - Fee Related
-
2012
- 2012-02-02 CY CY2012006C patent/CY2012006I2/el unknown
-
2013
- 2013-07-17 US US13/944,193 patent/US8859506B2/en not_active Expired - Fee Related
-
2014
- 2014-04-15 HU HUS1400024C patent/HUS1400024I1/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501161A5 (enExample) | ||
| CA2411590A1 (en) | Glycopeptide phosphonate derivatives | |
| US10117880B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| US9782421B1 (en) | Neridronic acid molecular complex for treating complex regional pain syndrome | |
| US10111837B2 (en) | Dosage forms for oral administration of zoledronic acid or related compounds | |
| US10173986B2 (en) | Methods for the safe administration of imidazole or imidazolium compounds | |
| US9999628B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| US9877977B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US10028969B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US10039774B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| JP2002543202A5 (enExample) | ||
| US9655908B2 (en) | Neridronic acid molecular complex for treating complex regional pain syndrome | |
| US20180280291A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
| US20180235985A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| US20180050053A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| JP2020063241A5 (enExample) | ||
| US20180133232A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US20170079998A1 (en) | Osteoclast inhibitors for knee conditions | |
| JP3705360B2 (ja) | 骨量低下疾患治療剤 | |
| US10350227B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| JP2009504783A5 (enExample) | ||
| JP2009526755A (ja) | Ｎ−（ホスホノアルキル）−アミノ酸、その誘導体及び組成物及びその利用法 | |
| CN1104091A (zh) | 双磷酸衍生物用于制备促进骨修复药物的应用 | |
| CN1646193A (zh) | 用于治疗和预防骨质疏松症的二膦酸 | |
| JP2007520452A5 (enExample) |